Want to see SE:CANTA full AI Analyst Report?

Cantargia AB (CANTA) Price & Analysis

3 Followers

CANTA Stock Chart & Stats

kr4.07

-kr0.02(-1.25%)

At close: Mar 06 4:00 PM EST

kr4.07

-kr0.02(-1.25%)

Day’s Range― - ―

52-Week Rangekr1.74 - kr6.59

Previous CloseN/A

Volume611.88K

Average Volume (3M)1.42M

Market Cap

kr513.70M

Enterprise Valuekr288.48M

Total Cash (Recent Filing)kr258.03M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)2.8

Beta0.84

Next Earnings

Aug 19, 2026

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.65

Shares Outstanding281,944,980

10 Day Avg. Volume1,074,033

30 Day Avg. Volume1,417,172

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)3.91

Price to Sales (P/S)3.28

P/FCF Ratio6.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr14.00

Price Target Upside243.98% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.63

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Cash GenerationTTM operating cash flow (158.1m) and free cash flow (157.6m) closely matching net income indicate high earnings quality. Durable cash generation can fund near-term R&D and operations, reduce immediate equity needs, and provide runway for clinical milestones over the next months.

Debt-free Balance SheetZero debt and conservative leverage materially lower financing and interest risk. A debt-free structure provides strategic optionality to support continued clinical development, partnerships or selective M&A without large fixed obligations, improving resilience over 2-6 months.

Focused IL1RAP Platform And Lead ProgramsA focused antibody platform targeting IL1RAP with oncology and inflammatory lead programs builds a clear scientific niche. Platform assets can be applied across indications and are attractive for partnerships or licensing, supporting durable strategic optionality and pipeline value.

Bears Say

Episodic Revenue HistoryThe company has a history of zero revenue and losses before the recent TTM uptick, and reporting notes current results may reflect non-recurring milestone/licensing income. This episodic revenue pattern undermines predictability of cash flows and sustainable operating margins.

Dependence On External Financing/partnersPrimary reliance on collaborations, grants and capital raising rather than product sales creates structural dependence on capital markets and partners. That elevates dilution and execution risk and limits stable, recurring operating cash generation over the medium term.

Equity Decline And Prior Cash BurnEquity has fallen to 234.0m from 265.9m (2025) and remains below earlier levels, reflecting past losses and dilution. Coupled with sizable 2021–2024 cash burn noted in cashflow commentary, this implies recurring funding needs and potential future dilution absent sustained product revenues.

Cantargia AB News

Cantargia schedules Q2 2026 results release and investor conference call

Cantargia AB ( ($SE:CANTA) ) has issued an announcement. Cantargia will publish its interim report for January to...

6d ago

Cantargia Expands Share Capital After Rights Issue Completion

Cantargia AB ( ($SE:CANTA) ) has provided an update. Cantargia AB has expanded its share capital following the...

10d ago

Cantargia: Nadunolimab’s Complementary Role in PDAC Supports Maintained Buy Rating and Reaffirmed $14 Target

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Cantargia AB, with...

1M ago

Cantargia Data Strengthen IL1RAP and Nadunolimab Case in Pancreatic Cancer

Cantargia AB ( ($SE:CANTA) ) has shared an update. Cantargia has reported new preclinical and clinical data in...

1M ago

Cantargia Raises SEK 75 Million in Undersubscribed Rights Issue and Grants Warrants to Fenja Capital

Cantargia AB ( ($SE:CANTA) ) has provided an announcement. Cantargia has completed a rights issue that was subscribed...

2M ago

Cantargia Highlights Nadunolimab’s Pancreatic Cancer Potential in Upcoming KOL Call

Cantargia AB ( ($SE:CANTA) ) just unveiled an update. Cantargia is organizing a key opinion leader call with...

2M ago

Cantargia: Buy Rating Reiterated on Nadunolimab Pipeline Progress and New Lung Nodule Trial; SEK14.00 Price Target Maintained

In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Cantargia AB, with...

2M ago

Cantargia Launches Phase 2 Prevention Trial of Nadunolimab in High‑Risk Lung Cancer Patients

Cantargia AB ( ($SE:CANTA) ) has issued an announcement. Cantargia has begun a Phase 2, investigator‑initiated trial of...

2M ago

Cantargia launches SEK 124m rights issue to fund antibody pipeline

The latest announcement is out from Cantargia AB ( ($SE:CANTA) ). Cantargia AB has published an information document...

2M ago

Cantargia Raises Up to SEK 199 Million to Advance Nadunolimab Oncology Pipeline

The latest update is out from Cantargia AB ( ($SE:CANTA) ). Cantargia AB has launched a SEK 124...

2M ago

CANTA FAQ

What was Cantargia AB’s price range in the past 12 months?

Cantargia AB lowest stock price was kr1.74 and its highest was kr6.59 in the past 12 months.

What is Cantargia AB’s market cap?

Cantargia AB’s market cap is kr513.70M.

When is Cantargia AB’s upcoming earnings report date?

Cantargia AB’s upcoming earnings report date is Aug 19, 2026 which is in 10 days.

How were Cantargia AB’s earnings last quarter?

Cantargia AB released its earnings results on May 19, 2026. The company reported -kr0.13 earnings per share for the quarter, beating the consensus estimate of -kr0.18 by kr0.05.

Is Cantargia AB overvalued?

According to Wall Street analysts Cantargia AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cantargia AB pay dividends?

Cantargia AB does not currently pay dividends.

What is Cantargia AB’s EPS estimate?

Cantargia AB’s EPS estimate is -0.17.

How many shares outstanding does Cantargia AB have?

Cantargia AB has 281,944,980 shares outstanding.

What happened to Cantargia AB’s price movement after its last earnings report?

Cantargia AB reported an EPS of -kr0.13 in its last earnings report, beating expectations of -kr0.18. Following the earnings report the stock price went down -1.18%.

Which hedge fund is a major shareholder of Cantargia AB?

Currently, no hedge funds are holding shares in SE:CANTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cantargia AB

Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.

Cantargia AB (CANTA) Earnings & Revenues

Historic Earnings Reports

CANTA Stock 12 Month Forecast

Average Price Target

kr14.00

▲(243.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"kr0","15":"kr15","3.75":"kr3.75","7.5":"kr7.5","11.25":"kr11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.822,2.758769230769231,3.6955384615384617,4.632307692307693,5.569076923076923,6.5058461538461545,7.442615384615385,8.379384615384616,9.316153846153846,10.252923076923079,11.189692307692308,12.126461538461538,13.06323076923077,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.822,2.758769230769231,3.6955384615384617,4.632307692307693,5.569076923076923,6.5058461538461545,7.442615384615385,8.379384615384616,9.316153846153846,10.252923076923079,11.189692307692308,12.126461538461538,13.06323076923077,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.822,2.758769230769231,3.6955384615384617,4.632307692307693,5.569076923076923,6.5058461538461545,7.442615384615385,8.379384615384616,9.316153846153846,10.252923076923079,11.189692307692308,12.126461538461538,13.06323076923077,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.235,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.225,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.185,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.49,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.802,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.158,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.104,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.822,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >